BMI View: Despite the strong growth potential of its pharmaceutical market, we believe Cameroon isunlikely to be of significant interest to multinational pharmaceutical firms. The country''s shortcomingsinclude poor public health provision and rampant corruption. Consequently we project that the fullpotential of the pharmaceutical sector will only be seen if major improvements are made to Cameroon''seconomy and government contributions to healthcare.Headline Expenditure Projections? Pharmaceuticals: XAF134.81bn (US$260mn) in 2012 to XAF153.17bn (US$310mn) in 2013; +13.6%in local currency terms and +20.3% in US dollar terms. Forecast upgraded from Q213, following<...
No comments:
Post a Comment